Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周新低，触及$0.36。这一显著下跌反映了公司正经历艰难时期，过去一年股价暴跌了-84.39%。根据 InvestingPro 数据，公司市值已萎缩至仅220万美元，而在过去十二个月中录得负EBITDA为-1205万美元。投资者一直密切关注公司表现，这一新低点标志着对其未来前景和市 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75 ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

In this article, we are going to take a look at where Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stands against the other cheap stocks insiders are buying recently. Why should we be interested ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Investing.com - Processa Pharmaceuticals (NASDAQ: PCSA) reported first quarter EPS of $-0.810, $0.49 worse than the analyst estimate of $-0.320. Revenue for the quarter came in at... ByInvesting ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs ...

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...